CLINICAL_TRIALS
trial_result
· 2019-10-31
Clinical Trial Update: BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) [Phase 2]
Summary
Phase 2 trial update for BELIEF study combining Bevacizumab and Erlotinib in EGFR-mutant non-small cell lung cancer; results posted after completion.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ETOP IBCSG Partners Foundation | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-10-31